Stem definition | Drug id | CAS RN |
---|---|---|
tyrosine kinase inhibitors | 785 | 302962-49-8 |
None
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 0.10 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 5.85 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 15 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Date | Agency | Company | Orphan |
---|---|---|---|
June 28, 2006 | FDA | BRISTOL MYERS SQUIBB |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Pleural effusion | 1145.26 | 18.33 | 560 | 15476 | 82392 | 46587634 |
Prescribed underdose | 312.39 | 18.33 | 127 | 15909 | 11926 | 46658100 |
Adverse event | 310.36 | 18.33 | 175 | 15861 | 34009 | 46636017 |
Cytogenetic analysis abnormal | 232.44 | 18.33 | 51 | 15985 | 525 | 46669501 |
Malignant neoplasm progression | 212.71 | 18.33 | 177 | 15859 | 64749 | 46605277 |
Philadelphia chromosome positive | 175.08 | 18.33 | 36 | 16000 | 263 | 46669763 |
Drug resistance | 168.63 | 18.33 | 93 | 15943 | 17275 | 46652751 |
Exposure via body fluid | 162.45 | 18.33 | 37 | 15999 | 457 | 46669569 |
Acute lymphocytic leukaemia recurrent | 150.21 | 18.33 | 47 | 15989 | 2048 | 46667978 |
Hospitalisation | 148.39 | 18.33 | 143 | 15893 | 63242 | 46606784 |
Pulmonary oedema | 144.24 | 18.33 | 128 | 15908 | 50977 | 46619049 |
Rash | 123.98 | 18.33 | 333 | 15703 | 356179 | 46313847 |
Pericardial effusion | 121.56 | 18.33 | 87 | 15949 | 25456 | 46644570 |
Blast crisis in myelogenous leukaemia | 114.39 | 18.33 | 28 | 16008 | 480 | 46669546 |
Chronic myeloid leukaemia | 107.55 | 18.33 | 38 | 15998 | 2420 | 46667606 |
Chylothorax | 103.17 | 18.33 | 23 | 16013 | 256 | 46669770 |
Fluid retention | 98.92 | 18.33 | 104 | 15932 | 50942 | 46619084 |
Nausea | 96.37 | 18.33 | 477 | 15559 | 686977 | 45983049 |
Diarrhoea | 85.98 | 18.33 | 399 | 15637 | 559203 | 46110823 |
Headache | 68.16 | 18.33 | 334 | 15702 | 478018 | 46192008 |
Fatigue | 67.77 | 18.33 | 397 | 15639 | 608300 | 46061726 |
Bone pain | 62.86 | 18.33 | 79 | 15957 | 46811 | 46623215 |
Death | 62.57 | 18.33 | 254 | 15782 | 335294 | 46334732 |
Chronic myeloid leukaemia transformation | 61.63 | 18.33 | 13 | 16023 | 109 | 46669917 |
Thrombocytopenia | 56.10 | 18.33 | 130 | 15906 | 126451 | 46543575 |
Large granular lymphocytosis | 51.76 | 18.33 | 12 | 16024 | 161 | 46669865 |
Blast cell crisis | 51.23 | 18.33 | 10 | 16026 | 54 | 46669972 |
Acute lymphocytic leukaemia | 51.20 | 18.33 | 23 | 16013 | 2750 | 46667276 |
Bone marrow transplant | 47.89 | 18.33 | 15 | 16021 | 655 | 46669371 |
Alopecia | 46.69 | 18.33 | 142 | 15894 | 162272 | 46507754 |
Therapeutic response delayed | 46.50 | 18.33 | 14 | 16022 | 535 | 46669491 |
Enterocolitis haemorrhagic | 46.03 | 18.33 | 18 | 16018 | 1522 | 46668504 |
Leukaemia recurrent | 45.21 | 18.33 | 17 | 16019 | 1292 | 46668734 |
Pancytopenia | 45.19 | 18.33 | 94 | 15942 | 84964 | 46585062 |
Fall | 44.81 | 18.33 | 29 | 16007 | 329068 | 46340958 |
Chronic myeloid leukaemia recurrent | 44.59 | 18.33 | 11 | 16025 | 195 | 46669831 |
Polymerase chain reaction positive | 41.01 | 18.33 | 8 | 16028 | 43 | 46669983 |
Aspiration pleural cavity | 40.96 | 18.33 | 14 | 16022 | 807 | 46669219 |
Product dose omission issue | 39.11 | 18.33 | 137 | 15899 | 168383 | 46501643 |
Drug hypersensitivity | 36.70 | 18.33 | 19 | 16017 | 243806 | 46426220 |
Lymphoid tissue hyperplasia | 36.14 | 18.33 | 9 | 16027 | 166 | 46669860 |
Dyspnoea | 35.71 | 18.33 | 300 | 15736 | 515248 | 46154778 |
Enterococcal bacteraemia | 35.45 | 18.33 | 14 | 16022 | 1215 | 46668811 |
Pulmonary hypertension | 35.11 | 18.33 | 52 | 15984 | 35941 | 46634085 |
Anaemia | 35.09 | 18.33 | 177 | 15859 | 255602 | 46414424 |
Platelet count decreased | 35.08 | 18.33 | 94 | 15942 | 99930 | 46570096 |
Nephrotic syndrome | 33.61 | 18.33 | 21 | 16015 | 4900 | 46665126 |
Myalgia | 32.01 | 18.33 | 104 | 15932 | 122984 | 46547042 |
Neutropenia | 28.65 | 18.33 | 111 | 15925 | 143093 | 46526933 |
Systemic candida | 27.55 | 18.33 | 15 | 16021 | 2712 | 46667314 |
Hepatitis chronic active | 27.50 | 18.33 | 6 | 16030 | 60 | 46669966 |
Condition aggravated | 26.58 | 18.33 | 27 | 16009 | 245025 | 46425001 |
Graft versus host disease | 25.86 | 18.33 | 20 | 16016 | 6568 | 46663458 |
Pleurisy | 25.02 | 18.33 | 21 | 16015 | 7741 | 46662285 |
Stem cell transplant | 24.43 | 18.33 | 12 | 16024 | 1754 | 46668272 |
Acne | 24.23 | 18.33 | 32 | 16004 | 19887 | 46650139 |
Hypotension | 23.69 | 18.33 | 27 | 16009 | 232562 | 46437464 |
Normal newborn | 23.08 | 18.33 | 18 | 16018 | 5983 | 46664043 |
Cytopenia | 22.96 | 18.33 | 20 | 16016 | 7748 | 46662278 |
Gene mutation identification test positive | 22.36 | 18.33 | 6 | 16030 | 150 | 46669876 |
Leukaemia | 22.35 | 18.33 | 14 | 16022 | 3281 | 46666745 |
Chronic graft versus host disease | 22.15 | 18.33 | 13 | 16023 | 2712 | 46667314 |
Infusion related reaction | 22.14 | 18.33 | 4 | 16032 | 101204 | 46568822 |
Acute graft versus host disease | 22.13 | 18.33 | 15 | 16021 | 4015 | 46666011 |
Demyelinating polyneuropathy | 21.84 | 18.33 | 8 | 16028 | 565 | 46669461 |
Lymphocytosis | 21.77 | 18.33 | 12 | 16024 | 2222 | 46667804 |
Cytomegalovirus colitis | 21.67 | 18.33 | 11 | 16025 | 1724 | 46668302 |
Therapy cessation | 21.14 | 18.33 | 35 | 16001 | 26594 | 46643432 |
Intentional product use issue | 20.96 | 18.33 | 52 | 15984 | 52728 | 46617298 |
Pulmonary arterial hypertension | 20.47 | 18.33 | 34 | 16002 | 25894 | 46644132 |
Gene mutation | 20.07 | 18.33 | 9 | 16027 | 1071 | 46668955 |
Toxicity to various agents | 20.06 | 18.33 | 26 | 16010 | 211740 | 46458286 |
Somnolence | 19.66 | 18.33 | 15 | 16021 | 156506 | 46513520 |
Subdural haematoma | 19.18 | 18.33 | 23 | 16013 | 12974 | 46657052 |
Full blood count decreased | 18.72 | 18.33 | 30 | 16006 | 22181 | 46647845 |
Skin toxicity | 18.65 | 18.33 | 13 | 16023 | 3641 | 46666385 |
White blood cell count decreased | 18.50 | 18.33 | 82 | 15954 | 112149 | 46557877 |
Blast cell proliferation | 18.39 | 18.33 | 3 | 16033 | 4 | 46670022 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Pleural effusion | 1524.04 | 16.44 | 749 | 14929 | 73317 | 29863483 |
Adverse event | 376.30 | 16.44 | 176 | 15502 | 15165 | 29921635 |
Drug resistance | 319.68 | 16.44 | 172 | 15506 | 19961 | 29916839 |
Philadelphia chromosome positive | 269.61 | 16.44 | 53 | 15625 | 178 | 29936622 |
Prescribed underdose | 257.31 | 16.44 | 110 | 15568 | 7649 | 29929151 |
Malignant neoplasm progression | 211.51 | 16.44 | 223 | 15455 | 72064 | 29864736 |
Hospitalisation | 176.67 | 16.44 | 162 | 15516 | 44157 | 29892643 |
Chronic myeloid leukaemia | 169.16 | 16.44 | 60 | 15618 | 2517 | 29934283 |
Blast crisis in myelogenous leukaemia | 168.86 | 16.44 | 42 | 15636 | 492 | 29936308 |
Cytogenetic analysis abnormal | 158.33 | 16.44 | 38 | 15640 | 379 | 29936421 |
Headache | 119.02 | 16.44 | 281 | 15397 | 182025 | 29754775 |
Chylothorax | 114.27 | 16.44 | 32 | 15646 | 608 | 29936192 |
Fluid retention | 110.63 | 16.44 | 97 | 15581 | 24901 | 29911899 |
Drug intolerance | 105.19 | 16.44 | 124 | 15554 | 45167 | 29891633 |
Pulmonary oedema | 101.47 | 16.44 | 120 | 15558 | 43855 | 29892945 |
Pericardial effusion | 95.46 | 16.44 | 83 | 15595 | 21061 | 29915739 |
Large granular lymphocytosis | 91.85 | 16.44 | 20 | 15658 | 123 | 29936677 |
Gene mutation | 89.40 | 16.44 | 28 | 15650 | 793 | 29936007 |
Fatigue | 89.24 | 16.44 | 367 | 15311 | 320306 | 29616494 |
Rash | 62.38 | 16.44 | 231 | 15447 | 191658 | 29745142 |
Acquired gene mutation | 61.20 | 16.44 | 23 | 15655 | 1138 | 29935662 |
Diarrhoea | 54.56 | 16.44 | 329 | 15349 | 333774 | 29603026 |
Acne | 52.88 | 16.44 | 42 | 15636 | 9394 | 29927406 |
Pulmonary hypertension | 52.45 | 16.44 | 57 | 15621 | 18979 | 29917821 |
Chronic myeloid leukaemia transformation | 51.30 | 16.44 | 13 | 15665 | 165 | 29936635 |
Blast cell proliferation | 49.90 | 16.44 | 8 | 15670 | 3 | 29936797 |
Loss of therapeutic response | 47.77 | 16.44 | 11 | 15667 | 90 | 29936710 |
Death | 47.42 | 16.44 | 334 | 15344 | 356949 | 29579851 |
Aspiration pleural cavity | 46.08 | 16.44 | 17 | 15661 | 798 | 29936002 |
Acute lymphocytic leukaemia recurrent | 42.85 | 16.44 | 23 | 15655 | 2644 | 29934156 |
Acute lymphocytic leukaemia | 39.82 | 16.44 | 23 | 15655 | 3049 | 29933751 |
Bone marrow transplant | 39.75 | 16.44 | 16 | 15662 | 952 | 29935848 |
Lymphoid tissue hyperplasia | 39.38 | 16.44 | 9 | 15669 | 71 | 29936729 |
Bone pain | 37.50 | 16.44 | 48 | 15630 | 18978 | 29917822 |
Hypotension | 35.14 | 16.44 | 32 | 15646 | 200533 | 29736267 |
Toxicity to various agents | 35.12 | 16.44 | 25 | 15653 | 177158 | 29759642 |
Intentional product use issue | 33.84 | 16.44 | 65 | 15613 | 36375 | 29900425 |
Product dose omission issue | 32.80 | 16.44 | 114 | 15564 | 91517 | 29845283 |
Therapy cessation | 32.72 | 16.44 | 40 | 15638 | 15097 | 29921703 |
Gene mutation identification test positive | 31.42 | 16.44 | 9 | 15669 | 186 | 29936614 |
Thrombocytopenia | 30.39 | 16.44 | 147 | 15531 | 136897 | 29799903 |
Chronic myeloid leukaemia recurrent | 29.91 | 16.44 | 8 | 15670 | 127 | 29936673 |
Natural killer cell count increased | 29.84 | 16.44 | 5 | 15673 | 4 | 29936796 |
Therapy change | 29.79 | 16.44 | 18 | 15660 | 2591 | 29934209 |
Pulmonary arterial hypertension | 27.64 | 16.44 | 29 | 15649 | 9272 | 29927528 |
Neoplasm recurrence | 26.95 | 16.44 | 15 | 15663 | 1852 | 29934948 |
Pleurisy | 26.66 | 16.44 | 21 | 15657 | 4639 | 29932161 |
Leukaemia recurrent | 26.60 | 16.44 | 14 | 15664 | 1547 | 29935253 |
Condition aggravated | 26.59 | 16.44 | 20 | 15658 | 137846 | 29798954 |
Platelet count decreased | 26.58 | 16.44 | 118 | 15560 | 106011 | 29830789 |
Chromosome analysis abnormal | 26.12 | 16.44 | 7 | 15671 | 112 | 29936688 |
Anterior interosseous syndrome | 25.86 | 16.44 | 5 | 15673 | 15 | 29936785 |
Clonal evolution | 25.78 | 16.44 | 7 | 15671 | 118 | 29936682 |
Hyphaema | 24.89 | 16.44 | 9 | 15669 | 399 | 29936401 |
Oedema | 24.41 | 16.44 | 63 | 15615 | 42930 | 29893870 |
Drug clearance decreased | 23.27 | 16.44 | 12 | 15666 | 1271 | 29935529 |
Blast cell crisis | 23.26 | 16.44 | 6 | 15672 | 82 | 29936718 |
Hyperplasia | 22.42 | 16.44 | 9 | 15669 | 532 | 29936268 |
Nausea | 22.18 | 16.44 | 245 | 15433 | 296712 | 29640088 |
Bradycardia | 21.73 | 16.44 | 4 | 15674 | 65522 | 29871278 |
Cytopenia | 21.48 | 16.44 | 24 | 15654 | 8232 | 29928568 |
Gelatinous transformation of the bone marrow | 20.94 | 16.44 | 4 | 15674 | 11 | 29936789 |
B-cell small lymphocytic lymphoma | 20.10 | 16.44 | 6 | 15672 | 144 | 29936656 |
Fall | 19.75 | 16.44 | 41 | 15637 | 181831 | 29754969 |
Rectosigmoid cancer | 19.57 | 16.44 | 6 | 15672 | 158 | 29936642 |
Acute kidney injury | 18.63 | 16.44 | 77 | 15601 | 273765 | 29663035 |
Allogenic bone marrow transplantation therapy | 18.60 | 16.44 | 4 | 15674 | 23 | 29936777 |
Cardiac arrest | 18.50 | 16.44 | 13 | 15665 | 92837 | 29843963 |
Hyperkalaemia | 18.07 | 16.44 | 6 | 15672 | 66004 | 29870796 |
Overdose | 17.89 | 16.44 | 11 | 15667 | 84326 | 29852474 |
Febrile neutropenia | 17.86 | 16.44 | 106 | 15572 | 106587 | 29830213 |
Hyperchromic anaemia | 17.80 | 16.44 | 4 | 15674 | 29 | 29936771 |
Pericarditis | 17.41 | 16.44 | 22 | 15656 | 8584 | 29928216 |
Loss of consciousness | 17.34 | 16.44 | 10 | 15668 | 79365 | 29857435 |
Pancytopenia | 17.24 | 16.44 | 89 | 15589 | 84963 | 29851837 |
Peripheral arterial occlusive disease | 16.96 | 16.44 | 17 | 15661 | 5151 | 29931649 |
Treatment failure | 16.86 | 16.44 | 48 | 15630 | 34631 | 29902169 |
Central nervous system leukaemia | 16.77 | 16.44 | 6 | 15672 | 258 | 29936542 |
Bone development abnormal | 16.48 | 16.44 | 4 | 15674 | 42 | 29936758 |
Source | Code | Description |
---|---|---|
ATC | L01EA02 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS PROTEIN KINASE INHIBITORS BCR-ABL tyrosine kinase inhibitors |
MeSH PA | D000970 | Antineoplastic Agents |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D047428 | Protein Kinase Inhibitors |
CHEBI has role | CHEBI:35610 | cytostatic |
CHEBI has role | CHEBI:38637 | tyrosine kinase inhibitors |
CHEBI has role | CHEBI:149553 | anti-coronaviral agents |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Blastic phase chronic myeloid leukemia | indication | 413656006 | |
Chronic phase chronic myeloid leukemia | indication | 413847001 | |
Philadelphia chromosome-positive acute lymphoblastic leukemia | indication | 425688002 | |
Philadelphia Chromosome Positive Chronic Myelocytic Leukemia | indication | ||
Chronic Myelocytic Leukemia Accelerated Phase | indication | ||
Acute hemorrhage | contraindication | 8573003 | |
Myocardial infarction | contraindication | 22298006 | DOID:5844 |
Torsades de pointes | contraindication | 31722008 | |
Body fluid retention | contraindication | 43498006 | |
Chronic heart failure | contraindication | 48447003 | |
Gastrointestinal hemorrhage | contraindication | 74474003 | |
Left heart failure | contraindication | 85232009 | |
Prolonged QT interval | contraindication | 111975006 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Edema | contraindication | 267038008 | |
Anemia | contraindication | 271737000 | DOID:2355 |
Cerebral hemorrhage | contraindication | 274100004 | |
Pregnancy, function | contraindication | 289908002 | |
Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
Neutropenic disorder | contraindication | 303011007 | DOID:1227 |
Pericardial effusion | contraindication | 373945007 | DOID:118 |
Ascites | contraindication | 389026000 | |
Breastfeeding (mother) | contraindication | 413712001 | |
Congenital long QT syndrome | contraindication | 442917000 | |
Pleural Effusions | contraindication |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 8.56 | acidic |
pKa2 | 7.72 | Basic |
pKa3 | 4.89 | Basic |
None
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
100MG | SPRYCEL | BRISTOL MYERS SQUIBB | N021986 | May 30, 2008 | RX | TABLET | ORAL | May 9, 2021 | PEDIATRIC EXCLUSIVITY |
140MG | SPRYCEL | BRISTOL MYERS SQUIBB | N021986 | Oct. 28, 2010 | RX | TABLET | ORAL | May 9, 2021 | PEDIATRIC EXCLUSIVITY |
20MG | SPRYCEL | BRISTOL MYERS SQUIBB | N021986 | June 28, 2006 | RX | TABLET | ORAL | May 9, 2021 | PEDIATRIC EXCLUSIVITY |
50MG | SPRYCEL | BRISTOL MYERS SQUIBB | N021986 | June 28, 2006 | RX | TABLET | ORAL | May 9, 2021 | PEDIATRIC EXCLUSIVITY |
70MG | SPRYCEL | BRISTOL MYERS SQUIBB | N021986 | June 28, 2006 | RX | TABLET | ORAL | May 9, 2021 | PEDIATRIC EXCLUSIVITY |
80MG | SPRYCEL | BRISTOL MYERS SQUIBB | N021986 | Oct. 28, 2010 | RX | TABLET | ORAL | May 9, 2021 | PEDIATRIC EXCLUSIVITY |
100MG | SPRYCEL | BRISTOL MYERS SQUIBB | N021986 | May 30, 2008 | RX | TABLET | ORAL | Dec. 21, 2021 | TREATMENT OF PEDIATRIC PATIENTS ONE YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINULLTION WITH CHEMOTHERAPY |
140MG | SPRYCEL | BRISTOL MYERS SQUIBB | N021986 | Oct. 28, 2010 | RX | TABLET | ORAL | Dec. 21, 2021 | TREATMENT OF PEDIATRIC PATIENTS ONE YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINULLTION WITH CHEMOTHERAPY |
20MG | SPRYCEL | BRISTOL MYERS SQUIBB | N021986 | June 28, 2006 | RX | TABLET | ORAL | Dec. 21, 2021 | TREATMENT OF PEDIATRIC PATIENTS ONE YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINULLTION WITH CHEMOTHERAPY |
50MG | SPRYCEL | BRISTOL MYERS SQUIBB | N021986 | June 28, 2006 | RX | TABLET | ORAL | Dec. 21, 2021 | TREATMENT OF PEDIATRIC PATIENTS ONE YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINULLTION WITH CHEMOTHERAPY |
70MG | SPRYCEL | BRISTOL MYERS SQUIBB | N021986 | June 28, 2006 | RX | TABLET | ORAL | Dec. 21, 2021 | TREATMENT OF PEDIATRIC PATIENTS ONE YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINULLTION WITH CHEMOTHERAPY |
80MG | SPRYCEL | BRISTOL MYERS SQUIBB | N021986 | Oct. 28, 2010 | RX | TABLET | ORAL | Dec. 21, 2021 | TREATMENT OF PEDIATRIC PATIENTS ONE YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINULLTION WITH CHEMOTHERAPY |
100MG | SPRYCEL | BRISTOL MYERS SQUIBB | N021986 | May 30, 2008 | RX | TABLET | ORAL | June 21, 2022 | PEDIATRIC EXCLUSIVITY |
140MG | SPRYCEL | BRISTOL MYERS SQUIBB | N021986 | Oct. 28, 2010 | RX | TABLET | ORAL | June 21, 2022 | PEDIATRIC EXCLUSIVITY |
20MG | SPRYCEL | BRISTOL MYERS SQUIBB | N021986 | June 28, 2006 | RX | TABLET | ORAL | June 21, 2022 | PEDIATRIC EXCLUSIVITY |
50MG | SPRYCEL | BRISTOL MYERS SQUIBB | N021986 | June 28, 2006 | RX | TABLET | ORAL | June 21, 2022 | PEDIATRIC EXCLUSIVITY |
70MG | SPRYCEL | BRISTOL MYERS SQUIBB | N021986 | June 28, 2006 | RX | TABLET | ORAL | June 21, 2022 | PEDIATRIC EXCLUSIVITY |
80MG | SPRYCEL | BRISTOL MYERS SQUIBB | N021986 | Oct. 28, 2010 | RX | TABLET | ORAL | June 21, 2022 | PEDIATRIC EXCLUSIVITY |
100MG | SPRYCEL | BRISTOL MYERS SQUIBB | N021986 | May 30, 2008 | RX | TABLET | ORAL | Nov. 9, 2024 | TREATMENT OF PEDIATRIC PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE |
140MG | SPRYCEL | BRISTOL MYERS SQUIBB | N021986 | Oct. 28, 2010 | RX | TABLET | ORAL | Nov. 9, 2024 | TREATMENT OF PEDIATRIC PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE |
20MG | SPRYCEL | BRISTOL MYERS SQUIBB | N021986 | June 28, 2006 | RX | TABLET | ORAL | Nov. 9, 2024 | TREATMENT OF PEDIATRIC PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE |
50MG | SPRYCEL | BRISTOL MYERS SQUIBB | N021986 | June 28, 2006 | RX | TABLET | ORAL | Nov. 9, 2024 | TREATMENT OF PEDIATRIC PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE |
70MG | SPRYCEL | BRISTOL MYERS SQUIBB | N021986 | June 28, 2006 | RX | TABLET | ORAL | Nov. 9, 2024 | TREATMENT OF PEDIATRIC PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE |
80MG | SPRYCEL | BRISTOL MYERS SQUIBB | N021986 | Oct. 28, 2010 | RX | TABLET | ORAL | Nov. 9, 2024 | TREATMENT OF PEDIATRIC PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE |
100MG | SPRYCEL | BRISTOL MYERS SQUIBB | N021986 | May 30, 2008 | RX | TABLET | ORAL | May 9, 2025 | PEDIATRIC EXCLUSIVITY |
140MG | SPRYCEL | BRISTOL MYERS SQUIBB | N021986 | Oct. 28, 2010 | RX | TABLET | ORAL | May 9, 2025 | PEDIATRIC EXCLUSIVITY |
20MG | SPRYCEL | BRISTOL MYERS SQUIBB | N021986 | June 28, 2006 | RX | TABLET | ORAL | May 9, 2025 | PEDIATRIC EXCLUSIVITY |
50MG | SPRYCEL | BRISTOL MYERS SQUIBB | N021986 | June 28, 2006 | RX | TABLET | ORAL | May 9, 2025 | PEDIATRIC EXCLUSIVITY |
70MG | SPRYCEL | BRISTOL MYERS SQUIBB | N021986 | June 28, 2006 | RX | TABLET | ORAL | May 9, 2025 | PEDIATRIC EXCLUSIVITY |
80MG | SPRYCEL | BRISTOL MYERS SQUIBB | N021986 | Oct. 28, 2010 | RX | TABLET | ORAL | May 9, 2025 | PEDIATRIC EXCLUSIVITY |
100MG | SPRYCEL | BRISTOL MYERS SQUIBB | N021986 | May 30, 2008 | RX | TABLET | ORAL | Dec. 21, 2025 | INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINULLTION WITH CHEMOTHERAPY |
140MG | SPRYCEL | BRISTOL MYERS SQUIBB | N021986 | Oct. 28, 2010 | RX | TABLET | ORAL | Dec. 21, 2025 | INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINULLTION WITH CHEMOTHERAPY |
20MG | SPRYCEL | BRISTOL MYERS SQUIBB | N021986 | June 28, 2006 | RX | TABLET | ORAL | Dec. 21, 2025 | INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINULLTION WITH CHEMOTHERAPY |
50MG | SPRYCEL | BRISTOL MYERS SQUIBB | N021986 | June 28, 2006 | RX | TABLET | ORAL | Dec. 21, 2025 | INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINULLTION WITH CHEMOTHERAPY |
70MG | SPRYCEL | BRISTOL MYERS SQUIBB | N021986 | June 28, 2006 | RX | TABLET | ORAL | Dec. 21, 2025 | INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINULLTION WITH CHEMOTHERAPY |
80MG | SPRYCEL | BRISTOL MYERS SQUIBB | N021986 | Oct. 28, 2010 | RX | TABLET | ORAL | Dec. 21, 2025 | INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINULLTION WITH CHEMOTHERAPY |
100MG | SPRYCEL | BRISTOL MYERS SQUIBB | N021986 | May 30, 2008 | RX | TABLET | ORAL | June 21, 2026 | PEDIATRIC EXCLUSIVITY |
140MG | SPRYCEL | BRISTOL MYERS SQUIBB | N021986 | Oct. 28, 2010 | RX | TABLET | ORAL | June 21, 2026 | PEDIATRIC EXCLUSIVITY |
20MG | SPRYCEL | BRISTOL MYERS SQUIBB | N021986 | June 28, 2006 | RX | TABLET | ORAL | June 21, 2026 | PEDIATRIC EXCLUSIVITY |
50MG | SPRYCEL | BRISTOL MYERS SQUIBB | N021986 | June 28, 2006 | RX | TABLET | ORAL | June 21, 2026 | PEDIATRIC EXCLUSIVITY |
70MG | SPRYCEL | BRISTOL MYERS SQUIBB | N021986 | June 28, 2006 | RX | TABLET | ORAL | June 21, 2026 | PEDIATRIC EXCLUSIVITY |
80MG | SPRYCEL | BRISTOL MYERS SQUIBB | N021986 | Oct. 28, 2010 | RX | TABLET | ORAL | June 21, 2026 | PEDIATRIC EXCLUSIVITY |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Mast/stem cell growth factor receptor Kit | Kinase | INHIBITOR | Kd | 9.24 | CHEMBL | CHEMBL | |||
Proto-oncogene tyrosine-protein kinase Src | Kinase | INHIBITOR | Kd | 9.68 | CHEMBL | CHEMBL | |||
Tyrosine-protein kinase Fyn | Kinase | INHIBITOR | Kd | 9.10 | CHEMBL | CHEMBL | |||
Tyrosine-protein kinase Yes | Kinase | INHIBITOR | Kd | 9.52 | CHEMBL | CHEMBL | |||
Ephrin type-A receptor 2 | Kinase | INHIBITOR | Kd | 9.07 | CHEMBL | CHEMBL | |||
Tyrosine-protein kinase Lck | Kinase | INHIBITOR | Kd | 9.70 | CHEMBL | CHEMBL | |||
Platelet-derived growth factor receptor beta | Kinase | INHIBITOR | Kd | 9.20 | CHEMBL | CHEMBL | |||
Tyrosine-protein kinase ABL1 | Kinase | INHIBITOR | IC50 | 9.60 | IUPHAR | CHEMBL | |||
Vascular endothelial growth factor receptor 1 | Kinase | Kd | 5.30 | CHEMBL | |||||
Serine/threonine-protein kinase mTOR | Kinase | IC50 | 4.46 | CHEMBL | |||||
Vascular endothelial growth factor receptor 2 | Kinase | Kd | 5.54 | CHEMBL | |||||
Fibroblast growth factor receptor 3 | Kinase | Kd | 5.41 | CHEMBL | |||||
Serine/threonine-protein kinase 35 | Kinase | Kd | 6.11 | CHEMBL | |||||
Platelet-derived growth factor receptor alpha | Kinase | Kd | 9.33 | CHEMBL | |||||
Casein kinase I isoform epsilon | Kinase | Kd | 5.82 | CHEMBL | |||||
Receptor-interacting serine/threonine-protein kinase 2 | Kinase | Kd | 7.51 | CHEMBL | |||||
Myelin transcription factor 1 | Unclassified | IC50 | 7.20 | CHEMBL | |||||
Ephrin type-B receptor 4 | Kinase | Kd | 9.47 | CHEMBL | |||||
Tyrosine-protein kinase JAK2 | Kinase | Kd | 6 | CHEMBL | |||||
Cyclin-G-associated kinase | Kinase | Kd | 8.59 | CHEMBL | |||||
Serine/threonine-protein kinase SBK1 | Kinase | Kd | 5.92 | CHEMBL | |||||
Aurora kinase A | Kinase | Kd | 5.03 | CHEMBL | |||||
MAP kinase p38 | Kinase | IC50 | 7 | CHEMBL | |||||
Tyrosine-protein kinase SYK | Kinase | Kd | 5.54 | CHEMBL | |||||
Wee1-like protein kinase | Kinase | Kd | 5.15 | CHEMBL | |||||
RAF proto-oncogene serine/threonine-protein kinase | Kinase | Kd | 6.24 | CHEMBL | |||||
Tyrosine-protein kinase BTK | Kinase | Kd | 8.85 | CHEMBL | |||||
Mitogen-activated protein kinase kinase kinase 13 | Kinase | Kd | 5.28 | CHEMBL | |||||
Ephrin type-A receptor 1 | Kinase | Kd | 8.39 | CHEMBL | |||||
Mitogen-activated protein kinase kinase kinase kinase 1 | Kinase | Kd | 6.01 | CHEMBL | |||||
Serine/threonine-protein kinase Nek11 | Kinase | Kd | 6.33 | CHEMBL | |||||
Serine/threonine-protein kinase B-raf | Kinase | Kd | 6.30 | CHEMBL | |||||
Tyrosine-protein kinase Fgr | Kinase | INHIBITOR | Kd | 9.30 | CHEMBL | ||||
Serine/threonine-protein kinase MRCK alpha | Kinase | Kd | 5.70 | CHEMBL | |||||
Mitogen-activated protein kinase kinase kinase 7 | Kinase | Kd | 5.43 | CHEMBL | |||||
Tyrosine-protein kinase FRK | Kinase | INHIBITOR | Kd | 9.51 | CHEMBL | ||||
Ephrin type-A receptor 8 | Kinase | Kd | 9.62 | CHEMBL | |||||
Ephrin type-A receptor 3 | Kinase | Kd | 10.03 | CHEMBL | |||||
Serine/threonine-protein kinase 10 | Kinase | Kd | 5.92 | CHEMBL | |||||
Tyrosine-protein kinase JAK3 | Kinase | Kd | 6.19 | CHEMBL | |||||
Tyrosine-protein kinase CSK | Kinase | Kd | 9 | CHEMBL | |||||
Serine/threonine-protein kinase TNNI3K | Kinase | Kd | 7.96 | CHEMBL | |||||
Receptor tyrosine-protein kinase erbB-2 | Kinase | Kd | 5.85 | CHEMBL | |||||
Tyrosine-protein kinase HCK | Kinase | INHIBITOR | Kd | 9.46 | CHEMBL | ||||
Fibroblast growth factor receptor 1 | Kinase | Kd | 5.43 | CHEMBL | |||||
Fibroblast growth factor receptor 2 | Kinase | Kd | 5.85 | CHEMBL | |||||
Chaperone activity of bc1 complex-like, mitochondrial | Kinase | Kd | 6.72 | CHEMBL | |||||
Serine/threonine-protein kinase 25 | Kinase | Kd | 5.47 | CHEMBL | |||||
Mitogen-activated protein kinase kinase kinase 4 | Kinase | Kd | 6.51 | CHEMBL | |||||
Mitogen-activated protein kinase kinase kinase kinase 5 | Kinase | Kd | 7.35 | CHEMBL | |||||
Misshapen-like kinase 1 | Kinase | Kd | 6.37 | CHEMBL | |||||
Serine/threonine-protein kinase 36 | Kinase | Kd | 6.68 | CHEMBL | |||||
Receptor tyrosine-protein kinase erbB-4 | Kinase | Kd | 7.26 | CHEMBL | |||||
Ephrin type-A receptor 6 | Kinase | Kd | 5.68 | CHEMBL | |||||
TRAF2 and NCK-interacting protein kinase | Kinase | Kd | 5.70 | CHEMBL | |||||
Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase | Kinase | Kd | 6.89 | CHEMBL | |||||
Aurora kinase B | Kinase | IC50 | 5.19 | CHEMBL | |||||
STE20-like serine/threonine-protein kinase | Kinase | Kd | 6.14 | CHEMBL | |||||
Bone morphogenetic protein receptor type-1B | Kinase | Kd | 7.28 | CHEMBL | |||||
Non-receptor tyrosine-protein kinase TYK2 | Kinase | Kd | 6.96 | CHEMBL | |||||
Serine/threonine-protein kinase 4 | Kinase | Kd | 5.42 | CHEMBL | |||||
Protein-tyrosine kinase 6 | Kinase | Kd | 8.11 | CHEMBL | |||||
Serine/threonine-protein kinase TAO2 | Kinase | Kd | 5.27 | CHEMBL | |||||
Serine/threonine-protein kinase Nek2 | Kinase | Kd | 5.19 | CHEMBL | |||||
Tyrosine-protein kinase Lyn | Kinase | INHIBITOR | Kd | 9.24 | CHEMBL | ||||
Cytoplasmic tyrosine-protein kinase BMX | Kinase | Kd | 8.85 | CHEMBL | |||||
Ephrin type-A receptor 5 | Kinase | Kd | 9.62 | CHEMBL | |||||
LIM domain kinase 1 | Kinase | Kd | 6.24 | CHEMBL | |||||
Ephrin type-A receptor 4 | Kinase | Kd | 8.92 | CHEMBL | |||||
Ephrin type-B receptor 1 | Kinase | Kd | 9.35 | CHEMBL | |||||
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform | Kinase | IC50 | 4.42 | CHEMBL | |||||
Activated CDC42 kinase 1 | Kinase | Kd | 8.25 | CHEMBL | |||||
Mitogen-activated protein kinase kinase kinase kinase 3 | Kinase | Kd | 6.19 | CHEMBL | |||||
Dual specificity testis-specific protein kinase 1 | Kinase | Kd | 7.48 | CHEMBL | |||||
Activin receptor type-1 | Kinase | Kd | 6.21 | CHEMBL | |||||
Serine/threonine-protein kinase MRCK gamma | Kinase | Kd | 5.92 | CHEMBL | |||||
Serine/threonine-protein kinase MRCK beta | Kinase | Kd | 5.68 | CHEMBL | |||||
Mitogen-activated protein kinase kinase kinase 2 | Kinase | Kd | 6.85 | CHEMBL | |||||
Serine/threonine-protein kinase ULK3 | Kinase | Kd | 5.34 | CHEMBL | |||||
Abelson tyrosine-protein kinase 2 | Kinase | Kd | 9.77 | CHEMBL | |||||
Serine/threonine-protein kinase 26 | Kinase | Kd | 5.72 | CHEMBL | |||||
Activin receptor type-2B | Kinase | Kd | 6.24 | CHEMBL | |||||
Tyrosine-protein kinase Blk | Kinase | INHIBITOR | Kd | 9.68 | CHEMBL | ||||
Receptor tyrosine-protein kinase erbB-3 | Kinase | Kd | 7.74 | CHEMBL | |||||
Ephrin type-B receptor 6 | Kinase | Kd | 10.41 | CHEMBL | |||||
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform | Kinase | IC50 | 4.52 | CHEMBL | |||||
Serine/threonine-protein kinase SIK2 | Kinase | Kd | 8.19 | CHEMBL | |||||
Serine/threonine-protein kinase TAO3 | Kinase | Kd | 5.64 | CHEMBL | |||||
Tyrosine-protein kinase Srms | Kinase | INHIBITOR | Kd | 7.89 | CHEMBL | ||||
Serine/threonine-protein kinase SIK3 | Kinase | Kd | 7.55 | CHEMBL | |||||
Dual specificity mitogen-activated protein kinase kinase; MEK1/2 | Kinase | IC50 | 5.77 | CHEMBL | |||||
Wee1-like protein kinase 2 | Kinase | Kd | 6.70 | CHEMBL | |||||
Macrophage colony-stimulating factor 1 receptor | Kinase | Kd | 9.24 | CHEMBL | |||||
Discoidin domain-containing receptor 2 | Kinase | Kd | 8.52 | CHEMBL | |||||
Serine/threonine-protein kinase receptor R3 | Kinase | Kd | 6.34 | CHEMBL | |||||
Activin receptor type-1B | Kinase | Kd | 6.48 | CHEMBL | |||||
Bone morphogenetic protein receptor type-1A | Kinase | Kd | 5.15 | CHEMBL | |||||
TGF-beta receptor type-1 | Kinase | Kd | 6.64 | CHEMBL | |||||
TGF-beta receptor type-2 | Kinase | Kd | 5.54 | CHEMBL | |||||
Eukaryotic translation initiation factor 2-alpha kinase 4 | Kinase | Kd | 5.80 | CHEMBL | |||||
Proto-oncogene tyrosine-protein kinase receptor Ret | Kinase | Kd | 6.41 | CHEMBL | |||||
Myotonin-protein kinase | Kinase | Kd | 5.89 | CHEMBL | |||||
Epithelial discoidin domain-containing receptor 1 | Kinase | Kd | 9.16 | CHEMBL | |||||
Mitogen-activated protein kinase kinase kinase kinase 4 | Kinase | Kd | 5.51 | CHEMBL | |||||
Activin receptor type-2A | Kinase | Kd | 6.68 | CHEMBL | |||||
Myosin light chain kinase 2, skeletal/cardiac muscle | Kinase | Kd | 5.46 | CHEMBL | |||||
Mitogen-activated protein kinase kinase kinase 19 | Kinase | Kd | 7.10 | CHEMBL | |||||
Ephrin type-B receptor 2 | Kinase | Kd | 9.41 | CHEMBL | |||||
Mitogen-activated protein kinase 11 | Kinase | Kd | 6.39 | CHEMBL | |||||
Dual specificity mitogen-activated protein kinase kinase 2 | Kinase | Kd | 5.85 | CHEMBL | |||||
Tyrosine-protein kinase TXK | Kinase | Kd | 8.68 | CHEMBL | |||||
Serine/threonine-protein kinase VRK2 | Kinase | Kd | 5.49 | CHEMBL | |||||
LIM domain kinase 2 | Kinase | Kd | 7.07 | CHEMBL | |||||
Ephrin type-B receptor 3 | Kinase | Kd | 8.16 | CHEMBL | |||||
Tyrosine-protein kinase Tec | Kinase | Kd | 7.89 | CHEMBL | |||||
Mitogen-activated protein kinase kinase kinase 3 | Kinase | Kd | 6.55 | CHEMBL | |||||
Serine/threonine-protein kinase NLK | Kinase | Kd | 6.59 | CHEMBL | |||||
Mitogen-activated protein kinase kinase kinase kinase 2 | Kinase | Kd | 5.89 | CHEMBL | |||||
Serine/threonine-protein kinase SIK1 | Kinase | Kd | 8.41 | CHEMBL | |||||
Mitogen-activated protein kinase 14 | Kinase | Kd | 7.57 | CHEMBL | |||||
Bcr/Abl fusion protein | Kinase | IC50 | 9.10 | CHEMBL | |||||
Breakpoint cluster region protein | Kinase | WOMBAT-PK | |||||||
Dual specificity mitogen-activated protein kinase kinase 5 | Kinase | Kd | 8.48 | CHEMBL | |||||
Mitogen-activated protein kinase kinase kinase MLT | Kinase | Kd | 7.35 | CHEMBL | |||||
Dual specificity mitogen-activated protein kinase kinase 1 | Kinase | Kd | 6 | CHEMBL | |||||
Receptor-type tyrosine-protein kinase FLT3 | Kinase | Kd | 5.49 | CHEMBL | |||||
Epidermal growth factor receptor | Kinase | Kd | 7.10 | CHEMBL | |||||
Proto-oncogene tyrosine-protein kinase Src | Kinase | Kd | 7.96 | CHEMBL | |||||
Tyrosine-protein kinase Blk | Kinase | IC50 | 8.10 | CHEMBL | |||||
Proto-oncogene tyrosine-protein kinase LCK | Kinase | Ki | 10.19 | CHEMBL | |||||
Calcium-dependent protein kinase 1 | Kinase | Kd | 6.19 | CHEMBL | |||||
Tubulin alpha-1A chain | Structural | Kd | 7.26 | CHEMBL |
ID | Source |
---|---|
4025488 | VUID |
N0000179780 | NUI |
D03658 | KEGG_DRUG |
863127-77-9 | SECONDARY_CAS_RN |
4025488 | VANDF |
C1328005 | UMLSCUI |
CHEBI:49375 | CHEBI |
1N1 | PDB_CHEM_ID |
CHEMBL1421 | ChEMBL_ID |
DB01254 | DRUGBANK_ID |
D000069439 | MESH_DESCRIPTOR_UI |
3062316 | PUBCHEM_CID |
5678 | IUPHAR_LIGAND_ID |
RBZ1571X5H | UNII |
475342 | RXNORM |
21648 | MMSL |
83173 | MMSL |
d05831 | MMSL |
011616 | NDDF |
422756008 | SNOMEDCT_US |
423658008 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
SPRYCEL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0003-0524 | TABLET | 70 mg | ORAL | NDA | 27 sections |
SPRYCEL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0003-0527 | TABLET | 20 mg | ORAL | NDA | 27 sections |
SPRYCEL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0003-0528 | TABLET | 50 mg | ORAL | NDA | 27 sections |
SPRYCEL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0003-0852 | TABLET | 100 mg | ORAL | NDA | 27 sections |
SPRYCEL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0003-0855 | TABLET | 80 mg | ORAL | NDA | 27 sections |
SPRYCEL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0003-0857 | TABLET | 140 mg | ORAL | NDA | 27 sections |
SPRYCEL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-5759 | TABLET | 70 mg | ORAL | NDA | 28 sections |